C14orf178: A Potential Drug Target for Various Diseases (G283579)

Target Name: C14orf178

NCBI ID: G283579

C14orf178

Other Name(s): C14orf178 variant 1 | Uncharacterized protein C14orf178 | chromosome 14 open reading frame 178 | CN178_HUMAN | Chromosome 14 open reading frame 178, transcript variant 1

C14orf178: A Potential Drug Target for Various Diseases

C14orf178 (C14orf178 variant 1) is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique genetic variation has led to a diverse expression profile, which has implications for its potential role in disease.

The C14orf178 gene is located on chromosome 14q34 and encodes a protein known as the long non-coding RNA (lncRNA) C14orf178. This lncRNA has been shown to play a role in regulating various cellular processes, including cell adhesion, migration, and survival.

One of the most significant aspects of C14orf178 is its variable exon patterns. There are four known exons, but each exon has a different length and has been shown to produce a distinct RNA product. The first exon has a repeat of 14 nucleotides, while the second exon has a insertion of a single nucleotide. The third and fourth exons contain variable-length insertions and deletions, respectively.

The variable exon patterns have led to a diverse expression profile for C14orf178. Studies have shown that C14orf178 can be expressed in various cell types, including human primary cells, patient-derived samples, and disease-specific cell samples. Additionally, the lncRNA has been shown to be expressed in various tissues and organs, including the brain, spinal cord, and heart.

C14orf178 has also been shown to play a role in several diseases and disorders. One of the most significant associations is with cancer. Studies have shown that high expression of C14orf178 is associated with poor prognosis in various types of cancer, including breast, ovarian, and colorectal cancers. Additionally, C14orf178 has been shown to promote the growth and survival of cancer cells, which may contribute to its role as a potential drug target.

Another potential drug target for C14orf178 is neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Studies have shown that C14orf178 is expressed in the brain and that it is involved in the development and progression of these diseases. Additionally, C14orf178 has been shown to protect against neurodegenerative diseases by regulating the expression of pro-inflammatory genes.

C14orf178 has also been shown to be involved in autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. Studies have shown that C14orf178 is expressed in the peripheral tissues and that it is involved in the development and progression of these autoimmune disorders. Additionally, C14orf178 has been shown to regulate the expression of immune cells and to promote the production of autoantibodies, which may contribute to its role in these disorders.

In conclusion, C14orf178 is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique genetic variation and diverse expression profile make it an attractive candidate for further research. Further studies are needed to determine the exact role of C14orf178 in these diseases and to develop effective therapies for these treatments.

Protein Name: Chromosome 14 Open Reading Frame 178

The "C14orf178 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C14orf178 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets